Search
AMG-119
go.drugbank.com/drugs/DB17363InvestigationalAMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).[A254811]
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalLifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by ...
Melperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. … It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP2D6 InhibitorsEnflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawnEnflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market. Unlike its other inhalational anesthetic counterparts including isoflurane and halothane...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalwith group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazolePazufloxacin
go.drugbank.com/drugs/DB11774InvestigationalPazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnThese heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting … Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH).
Products: HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 2 ENJEKTOR, HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 10 ENJEKTORLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD … [A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease
Synonyms: (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrateCategories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors